KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Gross Margin (2020 - 2023)

Historic Gross Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 66.23%.

  • AbCellera Biologics' Gross Margin fell 266400.0% to 66.23% in Q4 2023 from the same period last year, while for Dec 2023 it was 62.71%, marking a year-over-year decrease of 236100.0%. This contributed to the annual value of 55.68% for FY2024, which is 70300.0% down from last year.
  • Per AbCellera Biologics' latest filing, its Gross Margin stood at 66.23% for Q4 2023, which was down 266400.0% from 47.45% recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Gross Margin ranged from a high of 95.13% in Q2 2020 and a low of 47.45% during Q3 2023
  • Moreover, its 4-year median value for Gross Margin was 86.42% (2022), whereas its average is 81.45%.
  • As far as peak fluctuations go, AbCellera Biologics' Gross Margin skyrocketed by 85800bps in 2022, and later tumbled by -377200bps in 2023.
  • Over the past 4 years, AbCellera Biologics' Gross Margin (Quarter) stood at 87.72% in 2020, then dropped by -4bps to 84.29% in 2021, then rose by 10bps to 92.87% in 2022, then fell by -29bps to 66.23% in 2023.
  • Its last three reported values are 66.23% in Q4 2023, 47.45% for Q3 2023, and 61.8% during Q2 2023.